Renal dysfunction in chronic liver disease

Critical Care

Volumn 14, Issue 2, 2010, Pages

  Slack, Andy ^a   Yeoman, Andrew ^a   Wendon, Julia ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CONTRAST MEDIUM; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 18; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; URINARY KIDNEY INJURY MOLECULE 1; VASODILATOR AGENT;

ACUTE KIDNEY FAILURE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; EMERGENCY MEDICINE; FAMILIAL AMYLOID POLYNEUROPATHY; FATTY LIVER; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS C; HEPATORENAL SYNDROME; HUMAN; INTENSIVE CARE; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN RESTRICTION; REVIEW; RISK FACTOR; TREATMENT OUTCOME; CHRONIC DISEASE; LIVER DISEASE; PATHOPHYSIOLOGY;

CHRONIC DISEASE; HUMANS; KIDNEY FAILURE, ACUTE; LIVER DISEASES;

EID: 78149241660     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8855     Document Type: Review

References (55)

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538. 10.1016/j.jhep.2006.05.013, 16879891.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219. 10.1053/jhep.2003.50193, 12717402.
3. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009, 13:9-19. 2633261, 19240815.
4. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
5. Bash LD, Astor BC, Coresh J. Risk of incident ESRD: A comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010,
6. Luyckx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. Kidney Int 2005, (Suppl Aug):S68-77.
7. Sabry AA, Sobh MA, Irving WL, et al. A comprehensive study of the association between hepatitis C virus and glomerulopathy. Nephrol Dial Transpl 2002, 17:239-245.
8. Alavian SM. A shield against a monster: Hepatitis C in hemodialysis patients. World J Gastroenterol 2009, 15:641-646. 10.3748/wjg.15.641, 2653433, 19222088.
9. Appel G. Viral infections and the kidney: HIV, hepatitis B, and hepatitis C. Cleve Clin J Med 2007, 74:353-360. 10.3949/ccjm.74.5.353, 17506240.
10. Ohba S, Kimura K, Mise N, et al. Differential localization of s and e antigens in hepatitis B virus-associated glomerulonephritis. Clin Nephrol 1997, 48:44-47.
11. Russell RT, Pinson CW. Surgical management of polycystic liver disease. World J Gastro 2007, 13:5052-5059.
12. Snanoudj R, Durrbach A, Gauthier E, et al. Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation. Nephrol Dial Transpl 2004, 19:1779-1785.
13. Swan SK. The search continues-an ideal marker of GFR. Clin Chem 1997, 43:913-914.
14. Tomlanovich S, Golbetz H, Perlroth M, Stinson E, Myers BD. Limitations of creatinine in quantifying the severity of cyclosporine-induced chronic nephropathy. Am J Kidney Dis 1986, 8:332-337.
15. Takabatake T, Ohta H, Ishida Y, Hara H, Ushiogi Y, Hattori N. Low serum creatinine levels in severe hepatic disease. Arch Intern Med 1988, 148:1313-1315. 10.1001/archinte.148.6.1313, 3377614.
16. Slack AJ, Wendon J. The liver and kidney in critically ill patients. Blood Purif 2009, 28:124-134. 10.1159/000227281, 19590179.
17. Epstein M. Hepatorenal syndrome. Therapy in Nephrology and Hypertension - A companion to Brenner and Rector's The Kidney 1999, 45-50. WB Saunders, Mayland Heights, Brady HR, Wilcox CS.
18. Cholongitas E, Shusang V, Marelli L, et al. Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther 2007, 26:969-978.
19. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31. 10.1186/cc5713, 2206446, 17331245.
20. Kellum JA. Defining and classifying AKI: one set of criteria. Nephrol Dial Transpl 2008, 23:1471-1472.
21. Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN-time for reappraisal. Crit Care 2009, 13:211. 10.1186/cc7759, 19638179.
22. Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastro 2009, 15:67-80.
23. Abuelo J. Normotensive ischemic acute renal failure. N Engl J Med 2007, 357:797-805. 10.1056/NEJMra064398, 17715412.
24. Mandall MS, Lindenfield J, Tsou M-Y, Zimmerman M. Cardiac evaluation of liver transplant candidates. World J Gastro 2008, 12:3445-3451.
25. Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastro 2007, 13:5552-5559.
26. Gines P, Martin P-Y, Niederberger M. Prognostic significance of renal dysfunction in cirrhosis. Kidney Int 1997, 51(Suppl):S77-S82.
27. Garcia-Tsao G, Parikh CR, Viola A. Acute Kidney Injury in cirrhosis. Hepatology 2008, 48:2064-2077. 10.1002/hep.22605, 19003880.
28. Sheer TA, Runyon BA. Spontaneous bacterial peritonitis. Dig Dis 2005, 23:39-46. 10.1159/000084724, 15920324.
29. Sanyal A, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double blind placebo-controlled trial of terlipressin for type I hepatorenal syndrome. Gastroenterology 2008, 134:1360-1368. 10.1053/j.gastro.2008.02.014, 18471513.
30. Martin-Lahi M, Pepin M, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and heptorenal syndrome: a randomized study. Gastroenterology 2008, 134:1352-1359. 10.1053/j.gastro.2008.02.024, 18471512.
31. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review. Kidney Int 2008, 73:1008-1016. 10.1038/sj.ki.5002729, 18094679.
32. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365:1231-1238. 10.1016/S0140-6736(05)74811-X, 15811456.
33. Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004, 66:1115-1122. 10.1111/j.1523-1755.2004.00861.x, 15327406.
34. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005, 16:3046-3052. 10.1681/ASN.2005030236, 16148039.
35. Han WK, Waikar SS, Johnson A, et al. Urinary biomarkers for detection of acute kidney injury. Kidney Int 2008, 73:863-869. 10.1038/sj.ki.5002715, 2586909, 18059454.
36. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005, 294:813-818. 10.1001/jama.294.7.813, 16106006.
37. Niemann CU, Walia A, Waldman J, et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl 2009, 15:1852-1860. 10.1002/lt.21938, 19938135.
38. Kidney Disease Outcomes Quality Initiative Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266. 10.1016/S0272-6386(02)70081-4, 11904577, Kidney Disease Outcomes Quality Initiative.
39. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41. 10.1159/000180580, 1244564.
40. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305. 10.1056/NEJMoa041031, 15385656.
41. Bauer C, Melamed ML, Hostetter TH. Staging of Chronic Kidney Disease: Time for a Course Correction. J Am Soc Nephrol 2008, 19:844-846. 10.1681/ASN.2008010110, 18385419.
42. Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 1999, 10:2426-2439.
43. Winearls CG, Glassock RJ. Dissecting and refining the staging of chronic kidney disease. Kidney Int 2009, 75:1009-1014. 10.1038/ki.2009.49, 19242501.
44. Poggio ED, Rule AD. A critical evaluation of chronic kidney disease-should isolated reduced estimated glomerular filtration rate be considered a 'disease'?. Nephrol Dial Transpl 2008, 24:698-700.
45. Skulzacek PA, Szewc RG, Nolan CR, Riley DJ, Lee S, Pergola PE. Prediciton of GFR in liver transplant candidates. Am J Kidney Dis 2003, 42:1169-1176. 10.1053/j.ajkd.2003.08.017, 14655188.
46. Proulx NL, Akbari A, Garg AX, Rostom A, Jaffey J, Clark HD. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Trans 2005, 20:1617-1622.
47. Woitas RP, Stoffel-Wagner B, Flommersfeld S, et al. Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000, 46:712-715.
48. Poge U, Gerhardt T, Stoffel-Wagner B, Klehr HU, Sauerbruch T, Woitas RP. Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transpl 2006, 21:660-664.
49. Bolignano D, Coppolino G, Campo S, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transpl 2008, 23:414-416.
50. Neuberger JM, Gimson A, Davies M, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. GUT 2008, 57:252-257. 10.1136/gut.2007.131730, 17895356.
51. Bahirwani R, Reddy KR. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl 2009, 15(Suppl 2):S70-S74.
52. Bahirwani R, Campbell MS, Siropaides T, et al. Transplantation: impact of pretransplant renal insufficiency. Liver Transpl 2008, 14:665-671. 10.1002/lt.21367, 18433034.
53. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931-940. 10.1056/NEJMoa021744, 12954741.
54. Neuberger JM, Mamelokb RD, Neuhausc P, et al. Delayed Introduction of Reduced-Dose Tacrolimus, and Renal Function in Liver Transplantation: The 'ReSpECT' Study. Am J Transp 2009, 9:327-336.
55. EBPG Expert Group on Renal Transplantation European Best Practice Guidelines for Renal Transplantation. Section I: Evaluation, selection and preparation of the potential transplant recipient. Nephrol Dial Transplant 2000, 15(Suppl 7):3-38. EBPG Expert Group on Renal Transplantation.